indiancro Blog Posts
The world of competition
It's summertime here in India and same old rivalry has resurfaced- "Coca Cola Vs Pepsi"! It's been decades since these Cold drink giants are fighting over Indian beverage market share. Initially it was cold drink, but then the fight extended to other sections like energy drinks, healthy snacks, namkeens etc.
http://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=Industry%20Trends%20...
Side Effects
Big Pharma faces challenges to ensure profitability as a top priority function on its strategy agenda. The tasks faced by Big Pharma are uphill and some of them include maintaining sales of their existing products, some of the products going off patent face patent litigations from generic drug makers and lastly to "focus" or refocus on their clinical...
The risk factor in Sulphonyl ureas- An academic survey
The risk for overall mortality is similar in patients with type 2 diabetes receiving glipizide, glyburide,or glimepiride monotherapy, according to the results of a retrospective cohort study, reported online March 9 in Diabetes Care. However, the findings suggest that glimepiride may be the preferred sulfonylurea in patients with underlying coronary artery disease...
It's always hot" –Read Dr. Malcolm's experiences in India
I had first experienced India while working for a UK CRO and had been there as part of a vendor selection process, visiting units in Mumbai, Bangalore, and New Delhi. At this time I had been amazed by the cultural diversity of India. The ultra modern was juxtaposed with the archaic, affluence...
What will happen to the world of outsourcing?
The Pharma world space of 3 major global players has united to form the world's FIRST cancer group to focus towards the emerging markets of Asia to target Stomach and Lung cancer. The news release has got flashed at 6-7 major web sites. An individual news clip was flashed by Elli Lilly in the...
Veeda Hosts ACRO
Veeda Clinical research was the proud hosts to the ACRO meet at Fortune landmark, Ahmedabad. The flagship event was titled "Symbiosis-CRO and Sponsors."
The grand success of the seminar was on account of the Group Managing Director, Mr Apurva Shah and Director, Dr Kiran Marthak.
The function was graced by the presence of the key ACRO members and noted industry...
Not many treatment options in diabetes?
The numbers of new drugs developed for diabetes have been very less in the decade. The proven and effective treatments for Type I diabetes is insulin and the leaders of this therapeutic domain are Novo Nordisk, Sanofi and Elli Lilly. For type II diabetes, the most effective drugs are metformin and its analogues.
Other add on...
Stopping early can be harmful
Some of the randomized clinical trials if stopped early can lead to misleading results in the late phases according to a recent study in the Journal of the American Medical Association. The Randomized clinical trials provide a fair amount of evidence related to side effects. This can only beneficial if conducted as per the exact protocol...
Capitalize and grow
Forecast -
By 2012, analysts project that more than 65 percent of all FDA-regulated trials will take place outside the United States. This is reflected in the Indian biotechnology market, which is expected to grow at a compounded annual growth rate of 30 percent, and the Indian CRO market, which is expected to see growth of 49 percent annually.
Basis-
According...
The “changed” landscape of the Indian Pharma Industry
Background-
Indian pharma market & industry has been more of a provider of service to markets & consumers. But in recent time of pricing pressures in the Western world, increased Generic competition & regulatory hurdles pharma companies now look at India as a favorable market. The growth potential in India is tremendous...
61% are in Phase III
Latin America has proved to be an emerging market for clinical trials since the year 1999. According to latest statistics from the clinical trial gov. website, the trends in the rise of clinical trials particularly Brazil, Mexico and Argentina are extremely potential especially for the Phase II-Phase III trials. The trials which are outsourced in the...
Competition is every where
Competition for CRO's is rising everywhere and is has taken totally different turn in the recession phase. A Recent example of this is the takeover of healthcare life sciences IT company , Phase Forward by Oracle for US $ 685 million deal.
This will give new look to the existing data management outsourcing market. Will this market...
With Astellas Pharma and OSI Pharmaceuticals haggling over price, which biotech/biotechs could be next on the buyout menu? Mega-mergers might have been all the rage in 2009; however, with few targets left, the focus will shift to smaller acquisitions.
Some of the major Pharma-Biotech deals which have taken place since the month of December 2006 till date have been captured. The maximum...
Increasing Survival rates with limited options
Improving cancer survival rates are real success stories that sometime get lost in the noise over our healthcare system. However, "Targeted drugs are driving that survival in a major way.
Some cancer drugs like Sutent have proven effective for both stomach and kidney cancer and are likely to give benefits in both the cases as per...
Pharmacovigilance for “controversial” drugs
The Drug controlling authority in India has recently placed itself into action with reference to rules and regulations related to drug safety for various off patent drugs. The Off patent drugs despite "proven for safety" over the years with bio equivalence studies are still going to face the regulator's scanner. This means that adverse events all...
Veeda represented at Prime Ministers Meeting
Veeda represented at Prime Ministers Meeting
The Prime Minister of Malaysia, The Honourable Dato Sri Najib Tun Abdel Razak visited Malaysia on the 21st and 22nd of January and held a round table meeting with leading companies and individuals involved in the promotion of Malaysian-Indian business. The meeting was organised by the Malaysian Industrial Development...
Delays and pending approvals
1400 and still going strong! No certainly it is no sporting landmark in cricket. Neither it is score in nay indoor game. It is the score which signifies the number of pending ANDA applications from the Indian Pharma which are lying on the tables of the USFDA. This not only adds to the cost of healthcare of...
Creating a “VALUE” added position
Eyeing strategic deals in India has been the major focus of the global pharma companies who are stepping their feet in India particularly Pfizer and Glaxo.
Pfizer has gone south in establishing licensing cum marketing deal for its 30-40 products in 2009. Further, Glaxo last year has had strategic stake investment in
Dr. Reddy laboratories.
This deal gave the...
Drawbacks of generic Drug substitution- A theory
The need to curb the rising costs of healthcare has led policy makers in many countries to consider generic substitution of various brand name drugs as na effective means to cut costs.
For example, NHS in England began a 3-month consultation to seek views on plans to automatically substitute branded drugs with generic versions in...
The Investor gambles no more
Europe's biopharmaceutical sector is under severe pressure due to the reluctance of investors to gamble on high-risk drug development projects, according to a new report sponsored by the EU. Research-intensive companies have been hardest hit since the financial crisis began, with venture capitalizes shying away from niche bio pharma firms that can spend up to 15...
Being Adaptive in Phase I
Adaptive clinical trials today are the new approached to Drug development especially in oncology. The need for looking at adaptive clinical trials is being felt because of the drug developing companies because of the rising failures in Phase III clinical trials. Since enough is not known about a new chemical entity in early stages of clinical...
Acquisition specialists- TEVA
Teva, the world's biggest generic drug maker has blanket coverage in its presence especially in USA and Canada. The company with acquisitions before 2005 had managed to place itself in the European market of Italy. After the takeover of Barr in 2008 only which brought Teva, the European assets of Pliva (which Pliva took over form Merck), it...
While the behemoth health care reform bills have many positive attributes, patent reform will be critical to promote innovation, without which the health care industry will suffer. Some 26 years ago, The Hatch-Waxman Act attempted to reconcile the conflicting policies of increasing access to generic drugs while promoting innovation.
What has been the result of increased access to generic drugs? The...
Gone are the days
Their days of blistering growth behind them and facing a slide in bookings and revenue, U.S. outsourced drug-research service providers are striving to stand out in a crowded space through increased specialization and a push into emerging markets.
The contract research organizations (CRO) have to look to these strategies as clients seek low-cost options to revive their pipelines,...
Veeda Clinical Research Corporate Blog on internal news, views, happenings in the group and discussion about the industry subjects
http://blogs.veedacr.com/default.aspx...
Blog Links
Categories
Archives